1. Home
  2. HURA vs WRN Comparison

HURA vs WRN Comparison

Compare HURA & WRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • WRN
  • Stock Information
  • Founded
  • HURA 2009
  • WRN 2006
  • Country
  • HURA United States
  • WRN Canada
  • Employees
  • HURA N/A
  • WRN N/A
  • Industry
  • HURA
  • WRN Metal Mining
  • Sector
  • HURA
  • WRN Basic Materials
  • Exchange
  • HURA Nasdaq
  • WRN Nasdaq
  • Market Cap
  • HURA 246.9M
  • WRN 216.1M
  • IPO Year
  • HURA N/A
  • WRN N/A
  • Fundamental
  • Price
  • HURA $3.33
  • WRN $1.07
  • Analyst Decision
  • HURA Strong Buy
  • WRN Strong Buy
  • Analyst Count
  • HURA 1
  • WRN 1
  • Target Price
  • HURA $11.00
  • WRN $4.25
  • AVG Volume (30 Days)
  • HURA 216.5K
  • WRN 367.9K
  • Earning Date
  • HURA 03-04-2025
  • WRN 03-28-2025
  • Dividend Yield
  • HURA N/A
  • WRN N/A
  • EPS Growth
  • HURA N/A
  • WRN N/A
  • EPS
  • HURA N/A
  • WRN N/A
  • Revenue
  • HURA N/A
  • WRN N/A
  • Revenue This Year
  • HURA N/A
  • WRN N/A
  • Revenue Next Year
  • HURA N/A
  • WRN N/A
  • P/E Ratio
  • HURA N/A
  • WRN N/A
  • Revenue Growth
  • HURA N/A
  • WRN N/A
  • 52 Week Low
  • HURA $2.84
  • WRN $0.95
  • 52 Week High
  • HURA $14.60
  • WRN $1.66
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • WRN 50.61
  • Support Level
  • HURA N/A
  • WRN $1.07
  • Resistance Level
  • HURA N/A
  • WRN $1.14
  • Average True Range (ATR)
  • HURA 0.00
  • WRN 0.06
  • MACD
  • HURA 0.00
  • WRN -0.00
  • Stochastic Oscillator
  • HURA 0.00
  • WRN 46.67

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About WRN Western Copper and Gold Corporation

Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).

Share on Social Networks: